Murray Jensen Joins United Cannabis Corp Medical Board
September 13 2017 - 8:30AM
Access Wire
Jensen will Oversee Company's New Drug Application
(NDA) Process for Prana
DENVER, CO / ACCESSWIRE / September 13, 2017 /
United Cannabis Corporation (OTCQB: CNAB) (the "Company" or "United
Cannabis") today announced that Murray Jensen has joined the
Company's Medical Advisory Board and is tasked with overseeing the
Company's Investigational New Drug (IND) application process with
the Food and Drug Administration (FDA).
Mr. Jensen brings extensive expertise in drug development, with
over 25 years' experience in research for pharmaceutical, medical
device and natural health products in a wide variety of therapeutic
areas. He has held numerous senior clinical research positions at
pharmaceutical and biotechnology companies, and for the past 15
years has served as Managing Director of ethica CRO Inc. where he
is responsible for Business Operations and Clinical and Scientific
Affairs.
Commenting on the appointment, Mr. Jensen stated, "United
Cannabis has developed a noteworthy portfolio of phyto-therapeutic
products and I am very impressed with the results documented in
their preliminary testing, including their cannabis-centric Prana
line of medications. I look forward to working with the Company to
establish and implement the research protocols and IND applications
that will make these products available to a broader audience."
Earnest Blackmon, Chief Executive Officer of United Cannabis,
added, "Murray is a great addition to our Medical Board. His
expertise in the development and implementation of successful
clinical trials, as well as his experience in working with the FDA
will be invaluable as we begin testing our products in the clinic.
Now that we have secured a patent for the Prana product line, FDA
approval is our first priority, and we are excited to begin this
step with Murray at the helm."
Mr. Jensen earned a Master's Degree of Science in Medical
Science, Neuropathology, and served on the faculty at the
University of Calgary, Alberta, before embarking on a successful
career in drug development with companies in the global
pharmaceutical, biotechnology and CRO industries. He has also
published numerous manuscripts and peer-reviewed articles in
neurology, cardiology, dermatology, and clinical trial
methodology.
About United Cannabis Corporation
The Company's Prana Bio Medicinal products provide patients a
way to mix/match cannabinoids for therapeutic purpose. These
products, licensed to regulated marijuana dispensaries, are broken
into 5 categories that are available in capsules, sublinguals, and
topical delivery methods. The Company uses a patent-pending
infusion process utilizing select fatty acids, lipids, and specific
combination of cannabis-derived terpenes to increase
bioavailability.
For further information, please visit www.unitedcannabis.us.
Contact: Staff@UnitedCannabis.us
Phone: 303-386-7321
Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933, are subject to Rule 3b-6 under the
Securities Exchange Act of 1934, and are subject to the safe
harbors, created by those rules. All statements, other than
statements of fact, included in this release, including, without
limitation, statements regarding potential future plans and
objectives of the company, are forward-looking statements that
involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and other results and
further events could differ materially from those anticipated in
such statements. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying
the forward-looking statements.
SOURCE: United Cannabis Corporation